CB1 agonists possess neuroprotective properties with psychoactive side effects at effective doses, and CB2 agonists mainly mediate anti-inflammatory, suppression of microglia activation, neuroprotective, and immunomodulatory actions in animal models of neurodegenerative diseases [108]. This evidence concerns the gene CNR2 and neurodegenerative disease.